N/A N=67 Development of a Mindfulness-Based Treatment for the Reduction of Alcohol Use and Smoking Cessation
Tobacco Use · Alcohol Use, Unspecified
Primary: Aim 2: Number of Participants Scoring >3 — 18; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
N/A N=1,176 Project MADD - NIH Underage DUI and Ride
Underage Drinking · Driving Under the Influence · Drinking, Teen
Primary: Typical Weekend Drinking (DDQ) — 0.53; 0.53; 0.38 units on a scale — p=>0.05
N/A N=84 Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.
Covid19
Primary: Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on a Sample Collected by Healthcare Professionals. — 100; 98 percentage - Sensitivity and specificity
N/A N=23 Bedside Resources to Gauge Intravascular Volume Status
Hypovolemia · Craniosynostoses
Primary: Utility of Compensatory Reserve Index (CRI) Which Ranges From 0-1 in Order to Predict Fluid Responders From Non-responders — 0.06; 0.05 units on a scale
Phase 3 N=1,559 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population — 0.43; 1.80 mg/dL — p=<0.0001
N/A N=300 OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for Transplantation
Liver Transplantation · Liver Preservation for Transplant
Primary: Participants With Early Liver Allograft Dysfunction (EAD) — 27; 44; 27; 47 Participants — p=<0.0001
N/A N=6,266 Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT
Breast Cancer
Primary: Cancer Yield Per 1,000 — 5.0; 6.3; 4.9; 5.9 Cancer yield per 1,000 — p=0.005
Phase 3 N=52 Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Attention Deficit-Hyperactivity
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In — 37.2 score on a scale
Phase 2 N=8 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
Anal Canal Squamous Cell Carcinoma · Stage I Anal Cancer AJCC v8 · Stage II Anal Cancer AJCC v8
Primary: Acute Toxicity — 2 Participants
Phase 3 N=181 Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment — 41; 40; 41; 37 Participants
Phase 2 N=201 Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Leukemia · Acute Myeloid Leukemia · Acute Lymphocytic Leukemia
Primary: Non-Relapse Mortality Rate (NRM) — 2; 8 Participants
N/A N=162 Calypso Knee System Clinical Study, OUS
Osteoarthritis, Knee
Primary: Percentage of Participants With Composite Clinical Success (CCS) — 83.5; 57.2 percentage of subjects
N/A N=37 Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
Dry Eye
Primary: Subjective Comfort at End of Day With Contact Lens Wear — 72.5 score on a scale
Phase 4 N=100 ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion
Anemia
Primary: Postoperative Wound Infection (Superficial or Deep) or Other Perioperative Infection — 12; 3 Participants — p=.0122